These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 32546992)
21. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775 [TBL] [Abstract][Full Text] [Related]
22. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA; Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517 [TBL] [Abstract][Full Text] [Related]
24. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Rogers SL; Doody RS; Mohs RC; Friedhoff LT Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436 [TBL] [Abstract][Full Text] [Related]
25. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911 [TBL] [Abstract][Full Text] [Related]
26. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P; Bladström A; Stender K Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640 [TBL] [Abstract][Full Text] [Related]